Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib plus enzalutamide versus enzalutamide in men with prostate cancer
jRCT2080224595Phase 3Completed
- Start
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 3 trial of talazoparib and enzalutamide in prostate cancer (PCa) (2 arms). Started Mar 2019; status: completed.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080224595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224595.